PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jidLink to Publisher's site
 
J Infect Dis. 2012 June 15; 205(12): 1811–1815.
Published online 2012 April 5. doi:  10.1093/infdis/jis282
PMCID: PMC3415891

Effects of Short-Course Zidovudine on the Selection of Nevirapine-Resistant HIV-1 in Women Taking Single-Dose Nevirapine

Abstract

Single-dose nevirapine (sdNVP) given to prevent mother-to-child-transmission of HIV-1 selects NVP-resistance. Short-course zidovudine (ZDV) was hypothesized to lower rates of NVP-resistance. HIV-1 infected pregnant women administered sdNVP with or without short-course ZDV were assessed for HIV-1 mutations (K103N, Y181C, G190A, and V106M) prior to delivery and postpartum. Postpartum NVP-resistance was lower among 31 taking ZDV+sdNVP compared to 33 taking only sdNVP (35.5% vs 72.7%; χ2 P = .003). NVP mutants decayed to <2% in 24/35 (68.6%) at a median 6 months postpartum, with no differences based on ZDV use (logrank P = .99). Short-course ZDV was associated with reduced NVP-resistance mutations among women taking sdNVP.

Single-dose nevirapine (sdNVP) has been widely used in resource-limited settings to reduce mother-to-child-transmission (MTCT) of HIV-1 because of its simplicity and low cost [1]. However, sdNVP frequently selects HIV-1–resistant mutants in mothers [2], which may diminish the efficacy of subsequent NVP-containing antiretroviral treatment (ART) [3], and for this reason, alternative regimens for the prevention of MTCT (pMTCT) are currently preferred [4].

One pMTCT regimen endorsed by the World Health Organization (WHO) is sdNVP combined with zidovudine (ZDV) from ≥14 weeks gestation and ZDV and lamivudine (3TC) for a week postpartum [4]. This regimen is effective for preventing MTCT [5] and reducing postpartum NVP resistance [6]. However, it is not clear whether short-course ZDV alone, without 3TC, could similarly reduce NVP resistance, either by increasing the genetic barrier to resistance or reducing peripartum viral load when NVP selective pressure is highest. In studies reporting NVP resistance among women taking sdNVP and short-course antepartum ZDV only, NVP-resistance rates ranged from 17% to 75% [3, 79]. However, none of these studies included a comparison group of women who did not take ZDV.

We compared the selection of NVP-resistant HIV-1 in women receiving sdNVP with or without short-course ZDV in Beira, Mozambique. Since 2001, Mozambican guidelines endorsed sdNVP to prevent MTCT. In 2006, during enrollment of pregnant women into our observational study of HIV-1 drug resistance, short-course ZDV (initiated ≥32 weeks gestation) in addition to sdNVP was recommended (postpartum ZDV/3TC was implemented in early 2008). As clinics began offering ZDV, 2 cohorts of women, those who did and did not take ZDV, were created. We hypothesized that women who received ZDV in addition to sdNVP would have lower rates of selecting NVP-resistant HIV-1 mutants relative to those who received sdNVP alone.

METHODS

Study Design

An observational prospective cohort study of pregnant women in pMTCT programs in Beira, Mozambique, enrolled HIV-1–infected women who did not qualify for lifelong ART (criteria for lifelong ART = CD4 lymphocyte count <350 cells/uL or WHO clinical stage 4). One of 2 pMTCT regimens were prescribed by medical providers based on the national guidelines on the date women presented for prenatal care: sdNVP (200 mg) during labor, or sdNVP during labor with ZDV (300 mg orally 2 times a day) starting ≥32 weeks gestation and continuing for 1 week postpartum. Participants were excluded from this analysis if they took >1 dose of NVP, took any antiretroviral (ARV) medication other than sdNVP with or without short-course ZDV, or had NVP resistance prior to delivery. Blood was collected from women prior to delivery, and at 2, 4, 6, and 8 weeks, and 3, 4, 5, 6, 8, 10, 12, 18, and 24 months postpartum.

The study was approved by the Institutional Review Boards of Seattle Children's Hospital (Seattle, WA) and the Mozambique Ministry of Health (Maputo, Mozambique). Informed consent was obtained from all mothers prior to enrollment.

Measures

NVP-resistant HIV-1 mutants were evaluated in peripheral blood mononuclear cells with an oligonucleotide ligation assay (OLA) adapted to detect 4 common mutations in HIV-1 subtype C pol (K103N, V106M, Y181C, and G190A) [10]. HIV-1 DNA concentration was determined by amplification of gag. Predelivery samples, and 2 specimens from 2–8 weeks postdelivery (4- and 6-week specimens favored), were tested for NVP resistance. If NVP resistance was detected, subsequent samples were used to evaluate mutant decay.

Plasma HIV-1 RNA concentrations were measured at the first postpartum visit scheduled at 2 weeks after delivery (UltraSensitive AMPLICOR, Roche; or an in-house assay [11]). CD4 lymphocyte counts were abstracted from clinic records. Ingestion of sdNVP and use of other ARV medication were determined by participants’ self-report and confirmed with clinical records.

Statistical Analyses

The proportion with NVP-resistant HIV-1 between 2–8 weeks postpartum was determined, and 95% confidence intervals (CIs) estimated using the exact binomial method. NVP resistance was compared between those who did and did not take ZDV using χ-square (or Fisher exact) tests. Among those with resistance, peak mutant concentrations were compared in women who did and did not take ZDV using the Wilcoxon rank-sum test; and in women taking no ZDV, ZDV antepartum-only, and ZDV both ante- and postpartum, using the Kruskal-Wallis test. Associations between NVP resistance and ZDV exposure were evaluated with logistic regression, with adjustment for first postpartum viral load and last antepartum CD4 lymphocyte count. Among women with NVP-resistance mutations who took ZDV, the association between ZDV duration and peak mutant proportion was evaluated using Spearman rank correlation coefficient. Finally, among those with NVP resistance, the time to <2% (undetectable) mutant status was measured, and compared among those with and without ZDV exposure using the logrank test. A sensitivity analysis evaluated whether missed study visits affected this interval.

RESULTS

Of 201 pregnant women enrolled between June 2005 and May 2008, 64 participants remained in the analyses; most exclusions were due to loss to follow-up before (n = 74) or after (n = 21) delivery, or no sdNPV (n = 20). Thirty-one (48.4%) participants also took short-course ZDV for a median of 43 days (range 12, 86); all of these took ZDV antepartum (median 37 days; range 6, 78), and 21 also took ZDV postpartum (median 7 days; range 2, 28). While ZDV for pMTCT was introduced in 2006, 42.6% enrolled after 2006 did not take ZDV, most likely because HIV and prenatal care were suboptimally integrated. No differences in sociodemographic and clinical characteristics were detected between participants that did and did not take short-course ZDV (Table 1).

Table 1.
Characteristics of Study Participants

NVP Resistance and ZDV Exposure

Thirty-five (54.7%) of the 64 participants had NVP-resistance detected 2–8 weeks postpartum (data available on request). NVP-resistance mutations were fewer among those taking ZDV (n = 11/31, 35.5%; 95% CI 19.2, 54.6) compared to sdNVP only (n = 24/33, 72.7%; 95% CI 54.5, 86.7; χ2 P = .003). Resistance at each codon was more common in the sdNVP-only group, although only statistically significant (< .05) for the K103N and Y181C mutations (Figure 1). Among those with NVP-resistance mutations ≤8 weeks postpartum, the median peak mutant concentration was 16.2% (n = 35; range 2.0, 91.2), with codon K103N having the highest median peak (n = 29, median 15.4%; range 2.0, 91.2) followed by G190A (n = 15, median 11.2%; range 2.9, 83.8), V106M (n = 8, median 5.1%; range 2.5, 16.2), and Y181C (n = 13, median 3.9%; range 2.0, 18.0). Among those with NVP resistance, median peak mutant concentrations tended to be lower among those taking ZDV, although this was only significant for the G190A codon (median 4.1% vs 13.5%, P = .05), likely due to low numbers of participants.

Figure 1.
The proportion of mothers with detectable NVP resistance mutations 2–8 weeks postpartum, by exposure to ZDV. *P value calculated by χ2 test of independence. **P value calculated by Fisher exact test.

In multivariate analyses adjusted for the first postpartum plasma HIV-1 RNA load and CD4 lymphocyte count prior to delivery, short-course ZDV remained associated with fewer NVP-resistance mutations compared with sdNVP only (odds ratio [OR] 0.2, 95% CI .06, .7). However, the multivariate model revealed a significant (P < .05) interaction between ZDV and the first postpartum viral load; viral load was only associated with NVP resistance among those who did not take ZDV (Supplementary Figure 1).

NVP Resistance and ZDV Timing/Duration

The proportion of participants with NVP resistance was similar among women taking ZDV both ante- and postpartum (n = 21, 33.3%; 95% CI 11.3, 55.3) and antepartum only (n = 10, 40.0%; 95% CI 3.1, 76.9; Fisher exact, P = 1.0). Both groups had less NVP resistance compared to participants without ZDV, although this was significant only for those taking ZDV both ante- and postpartum (OR 0.2 for ZDV ante- and postpartum vs no ZDV; 95% CI .05, .7; P = .005; OR 0.3 for ZDV antepartum-only vs no ZDV; 95% CI .05, 1.2; P = .06). Among those with NVP-resistance, peak concentration of mutants were similar in all groups (> .10, Kruskal-Wallis), although comparisons were limited by low numbers of participants.

Among women taking ZDV, NVP-resistance was not associated with the total, antepartum, or postpartum duration of ZDV exposure (Wilcoxon rank-sum P = .26, .26, and .93, respectively). In the women with NVP resistance, the peak concentration of mutant virus was also not associated with ZDV duration overall (n = 11, Spearman ρ −0.33; P = .32), antepartum (n = 11, Spearman ρ 0.53; P = .09), or postpartum (n = 7, Spearman ρ 0.54; P = .22).

NVP Resistance Decay and ZDV Exposure

Follow-up specimens from the 35 women with NVP resistance ≤8 weeks postpartum were available through a median of 12 months postpartum (range 1–24). In most of these women (n = 24/35, 68.6%; 95% CI 50.7, 83.1), mutant viruses decayed below the limit of detection (<2%) at a median of 6 months postpartum (range 2–24). The time to first undetectable specimen did not differ by ZDV status (logrank P = .99). Sensitivity analyses assessing the impact of missing observations showed similar results. Notably, after NVP-resistance mutations decayed to <2%, mutations were detected at low concentrations in subsequent specimens from 2 women without documentation of additional NVP ingestion, at 18 and 24 months postpartum.

A reverse Kaplan-Meier curve examining NVP resistance over time since sdNVP for all (n = 64) subjects suggests that 96.8% had <2% mutant by 12 months postpartum (Supplementary Figure 2). Two women did not achieve mutant-free status by 12 months postpartum: 1 (ZDV group) had no specimens >12 months (lost to follow-up), and the other (no ZDV group) had a mutant-free specimen at 24 months.

DISCUSSION

In this observational study, the addition of short-course ZDV for a median of 6 weeks duration to sdNVP was associated with a substantial reduction in postpartum selection of NVP-resistant HIV-1. While not randomized, women's baseline characteristics were similar regardless of ZDV use, and ZDV use was most influenced by the prevailing guidelines during their pregnancy.

Postpartum plasma viral load was associated with the selection of resistant viruses, but only among subjects who did not take ZDV. The lesser rate of NVP resistance across all plasma viral loads in women taking ZDV illustrates the greater genetic barrier to selecting resistance posed by combining ZDV with sdNVP. ZDV resistance requires multiple mutations and transpires over weeks to months [12], making it unlikely that an individual would harbor HIV-1 variants with mutations conferring both ZDV and NVP resistance either spontaneously or as a result of short-term ZDV exposure, as in this study.

Our study may not have observed the maximal effect of ZDV, as a third of the women did not continue ZDV postpartum as recommended by national guidelines. After delivery, as intracellular ZDV concentrations wane, selective pressure of NVP could select mutant viruses, diminishing the effect of ZDV. While continuing ZDV postpartum should theoretically be superior at preventing NVP resistance compared with antepartum ZDV only, our comparisons were limited by the low number of subjects.

In the majority of women with NVP resistance, mutant viruses decayed below detection by 12 months postpartum, similar to prior studies [2, 13]. While the rate of decay did not vary by ZDV exposure, the ZDV group had a greater proportion of mutant-free women across all time points. Of note, a few women had very low concentrations of NVP-resistant mutants detected after becoming undetectable on at least one earlier time point. We did not evaluate whether these mutants were replication competent, although our study of Thai women suggests that the clinically significant threshold concentration of NVP mutants detected by OLA is >5% [14].

Our study has several limitations. First, exclusions and variable follow-up limited the power of our comparative analyses. Second, the short duration of ZDV use limited our examination of whether longer antepartum ZDV durations select ZDV-resistant viruses and reduce its barrier to NVP resistance. Third, a single viral load approximately 2 weeks postpartum may be an imperfect surrogate for viral replication between 0–3 weeks postpartum during NVP selective pressure. Fourth, self-report of ARV medications other than sdNVP is subject to recall bias. Finally, predelivery specimens were missing from 12 participants: 8 had no postpartum NVP resistance and were likely wild-type prepartum, and 4 (3 sdNVP only, 1 ZDV+sdNVP) had NVP resistance postpartum that decayed briskly to undetectable levels, making antepartum NVP resistance unlikely. Repeating analyses excluding these 4 participants did not substantially change our findings.

In conclusion, short-course (median 6 weeks) ZDV reduced selection of NVP resistance in women taking sdNVP for pMTCT. To our knowledge, no study has directly compared rates of NVP resistance between short-course ZDV and the current WHO-recommended postpartum combination of ZDV and 3TC. While 3TC has relatively few toxicities and is inexpensive, dispensing the regimen postpartum is impractical when women deliver at home, and selection of 3TC resistance with this combination [6, 15] could threaten the efficacy of later ART. These issues provide a rationale for trials to evaluate short-course ZDV alone compared to postpartum ZDV and 3TC following sdNVP.

Supplementary Data

Supplementary materials are available at The Journal of Infectious Diseases online (http://www.oxfordjournals.org/our_journals/jid/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Supplementary Data:

Notes

Acknowledgments. The authors would like to thank participating women and infants, the Mozambican Ministry of Health staff, the study team and the laboratory staff for important contributions to this study, and Dr. Joseph E. Fitzgibbon at the US National Institutes of Health for valuable advice and guidance. The study team and laboratory staff involved with this study received compensation for their participation.

Financial support. This work was supported by a National Institutes of Health (NIH) grant award (to L. M. F., R01 AI058723). M. A. M. was also supported in part by an NIH STD/AIDS Research Training Grant (T32 AI07140). The funding agencies were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. WHO. Prevention of mother-to-child transmission of HIV: selection and use of nevirapine. Geneva: World Health Organization; 2001.
2. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) AIDS. 2001;15:1951–7. [PubMed]
3. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229–40. [PubMed]
4. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV Infection in infants: Recommendations for a public health approach. Geneva: World Health Organization; 2010.
5. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217–28. [PubMed]
6. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 2009;6:e1000172. [PMC free article] [PubMed]
7. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS. 2006;20:1281–8. [PubMed]
8. van Zyl GU, Claassen M, Engelbrecht S, et al. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. J Med Virol. 2008;80:942–6. [PubMed]
9. Lehman DA, Chung MH, Mabuka JM, et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr. 2009;51:522–9. [PMC free article] [PubMed]
10. Micek MA, Blanco AJ, Beck IA, et al. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin Infect Dis. 2010;50:1405–14. [PMC free article] [PubMed]
11. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007;196:1500–8. [PubMed]
12. Boucher CA, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis. 1992;165:105–10. [PubMed]
13. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA. 2006;103:7094–9. [PubMed]
14. Jourdain G, Wagner TA, Ngo-Giang-Huong N, et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis. 2010;50:1397–404. [PMC free article] [PubMed]
15. Farr SL, Nelson JA, Ng'ombe TJ, et al. Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr. 2010;54:515–23. [PMC free article] [PubMed]

Articles from The Journal of Infectious Diseases are provided here courtesy of Oxford University Press